Skip to main content
Premium Trial:

Request an Annual Quote

PrimeraDx Gets FDA Clearance for System, C. Difficile Assay

NEW YORK (GenomeWeb News) – PrimeraDx said that it has received US Food and Drug Administration 510(k) clearance for its ICEPlex System and ICEPlex C. difficile Assay Kit.

The ICEPlex System is a quantitative multiplex PCR system and can run panels of such diverse analytes as mRNAs, microRNAs, and genomic loci. The platform runs an assay technology called scalable target amplification routine, or STAR, which integrates standard endpoint PCR with capillary electrophoresis to simultaneously quantitatively measure multiple target nucleic acids.

The ICEPlex C. difficile Assay Kit detects Clostridium difficile in human stool samples.

PrimeraDx CEO and President Matt McManus said in a statement that the FDA clearances were "clearly a major step forward for the company," and noted that the firm is developing multi-analyte tests for oncology and infectious disease applications.

As reported recently by PCR Insider, Mansfield, Mass.-based PrimeraDx is undergoing a restructuring, which has forced the firm to downsize, and it is attempting to raise additional funding.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.